Global Lithium Resources has successfully wrapped up its 2023 drilling campaign at the Manna lithium project, a property it fully owns in Western Australia.
Situated approximately 100km east of Kalgoorlie in the Goldfields region, the 2023 drilling program at the Manna project marked the second major drilling initiative and encompassed over 60,000 meters of drilling.
K-Drill and Profile Drilling, responsible for conducting the reverse circulation drilling program at Manna in 2022, were joined by DDH1 Drilling, a firm that had previously carried out metallurgical diamond drilling at the project, to complete the drilling campaign, spanning over 100km.
Global Lithium’s General Manager of Geology, Logan Barber, expressed enthusiasm, stating, “This is an exciting time for Global Lithium as we have now drilled over 60,000m at the Manna lithium project during 2023 and now await assays to feed into the MRE (mineral resource estimate) update.”
The primary focus of the drilling program was expansion and infill drilling of the Manna Mineral Resource Estimate (MRE), which presently stands at 36 million tonnes at 1.13 percent lithium oxide. It specifically aimed to explore extensions along the strike and down-dip of the Manna lithium deposit. Additionally, geotechnical drilling was conducted to support the project’s definitive feasibility study, expected to conclude in the second quarter of the 2024 calendar year (Q2 CY24).
Barber commended the exploration team’s dedication to the program, stating, “Our exploration team has worked incredibly hard throughout this program while maintaining a high level of safety.”
“With drilling now complete, we will begin to update the market as results come to hand from this program, building on the initial results previously announced in October.”
Barber also noted, “Significant upside still exists at the Manna project with the system still open to the north-east and south-west. Targeting and planning for further drilling in 2024 has already begun.”
The publication of the Manna lithium project’s MRE is expected in Q1 CY24, contingent upon the receipt of assay results from the 2023 program.